Program Disclaimers
Important safety information, medication-specific disclosures, and program terms.
Effective Date: April 24, 2026
Entity: CaliberRx LLC
Website: caliberrx.co
THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND
HOW YOU CAN GET ACCESS TO THIS INFORMATION. PLEASE REVIEW IT CAREFULLY.
1. About CaliberRx
CaliberRx LLC (“CaliberRx,” “we,” “our,” or “us”) is a management services organization (MSO) that provides
administrative, marketing, technology coordination, and non-clinical support services to facilitate patient access to
telehealth consultations and prescription medications. CaliberRx does not practice medicine, pharmacy, nursing, or any
other licensed healthcare profession.
All medical consultations, prescribing decisions, and clinical judgment are performed by independently licensed
healthcare providers operating on a HIPAA-compliant telehealth platform. All prescriptions are filled by licensed
pharmacies engaged through the platform’s pharmacy network. CaliberRx does not prescribe, compound, dispense, or
fulfill prescriptions, and does not direct, control, or interfere with the independent clinical judgment of any licensed
provider or pharmacist.
Eligibility for any medication is determined solely by the evaluating clinician based on an individual patient’s medical
history, current health status, and applicable state and federal law. CaliberRx makes no representation or promise that
any patient will be prescribed a particular medication or any medication at all.
2. General Medical Disclaimer
Information provided through the CaliberRx website, communications, marketing, or any associated materials is for
general educational and informational purposes only. It is not intended as, and should not be interpreted as, medical
advice, a professional diagnosis, a treatment plan, or a prescription. Nothing on our website creates a patient-provider
relationship with CaliberRx. A patient-provider relationship is established only after a licensed clinician accepts you for
care through the telehealth platform.
Do not delay seeking medical attention or disregard professional medical advice because of information you have read
on our website or in our communications. If you believe you are experiencing a medical emergency, call 911 or proceed
immediately to the nearest emergency department.
3. Medication Safety Information
The sections below summarize important safety information for the medications coordinated through CaliberRx at this
time. This is not a complete description of risks, warnings, contraindications, or adverse reactions. The full Prescribing
Information issued by the manufacturer (for FDA-approved products) or by the dispensing compounding pharmacy (for
compounded preparations) is the authoritative source and will be provided with your medication.
3.1 Semaglutide (GLP-1 Receptor Agonist)
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Branded forms include Ozempic®, Wegovy®, and
Rybelsus® (registered trademarks of Novo Nordisk A/S; CaliberRx is not affiliated with, endorsed by, or sponsored by
Novo Nordisk A/S — see Section 5). Where the semaglutide coordinated through the platform is a compounded
preparation, additional disclosures under “Compounded Product Notice” below apply.
Important Safety Information — Thyroid C-Cell Tumors. In rodent studies, semaglutide caused dose- and
duration-dependent thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). Whether semaglutide
causes thyroid C-cell tumors, including MTC, in humans is unknown. Do not use semaglutide if you or any
family member has a history of medullary thyroid carcinoma or if you have been diagnosed with Multiple
Endocrine Neoplasia syndrome type 2 (MEN 2). Contact your clinician promptly if you develop symptoms that
may indicate a thyroid tumor, such as a new lump or swelling in the neck, persistent hoarseness, trouble
swallowing, or shortness of breath.
Warnings and Precautions
The warnings and precautions listed for semaglutide in Section 3.1 also apply to tirzepatide, including but not limited to:
acute pancreatitis, acute gallbladder disease, hypoglycemia (particularly with concurrent insulin or sulfonylurea use),
acute kidney injury from dehydration, serious hypersensitivity reactions including anaphylaxis and angioedema, diabetic
retinopathy complications, mental health changes including new or worsening depression or suicidal ideation, severe
gastrointestinal disease, and pulmonary aspiration risk during anesthesia or deep sedation. Disclose your complete
medical history to your clinician before starting therapy.
Additional considerations specific to tirzepatide:
- Oral contraceptive effectiveness. Tirzepatide may reduce the efficacy of oral hormonal contraceptives, particularly when therapy is initiated and for four weeks after each dose escalation. Patients who can become pregnant should use a non-oral contraceptive method during these periods or add a barrier method of contraception. Discuss appropriate contraception with your clinician.
- Pregnancy and lactation. Tirzepatide may cause fetal harm. Do not use if pregnant, attempting to become pregnant, or breastfeeding. Discontinue at least two months prior to a planned pregnancy.
- Alcohol. Avoid alcohol while taking tirzepatide.
- Never share. Do not share pens, needles, syringes, or vials with another person.
Common Side Effects
The side-effect profile of tirzepatide is similar to that of semaglutide. Commonly reported adverse effects include nausea,
vomiting, diarrhea, constipation, abdominal pain, indigestion, decreased appetite, injection site reactions, fatigue,
dizziness, headache, altered taste, back pain, and elevated pancreatic enzymes on laboratory testing. Hypoglycemia
may occur in patients with Type 2 diabetes, particularly when tirzepatide is combined with other glucose-lowering agents.
Gastrointestinal effects are most common during dose escalation and often diminish over time. Notify your clinician if side
effects are severe or persistent.
Drug Interactions
As with semaglutide, tirzepatide delays gastric emptying and may affect the absorption of oral medications. Important
interactions include increased hypoglycemia risk with insulin or sulfonylureas, potential effects on the absorption of
narrow-therapeutic-index oral drugs (such as warfarin), potential effects on oral thyroid hormone absorption, and the
reduction in oral contraceptive effectiveness described above. Disclose all prescription medications, over-the-counter
products, and herbal supplements to your clinician before starting therapy.
To report a suspected adverse reaction, contact the FDA MedWatch program at 1-800-FDA-1088 or
www.fda.gov/medwatch (http://www.fda.gov/medwatch), and notify your prescribing clinician. In a medical emergency,
call 911 or proceed immediately to the nearest emergency department.
3.3 NAD+ Optimization (Nicotinamide Adenine Dinucleotide)
Nicotinamide Adenine Dinucleotide (NAD+) is a naturally occurring coenzyme involved in cellular energy production, DNA
repair, and metabolic regulation. NAD+ is coordinated through CaliberRx as a compounded preparation prepared by a
licensed 503A compounding pharmacy pursuant to a patient-specific prescription. NAD+ in injectable or intranasal form is
not an FDA-approved drug product for the uses discussed in connection with the CaliberRx program.
Important Safety Information. Compounded NAD+ is not evaluated or approved by the FDA for the treatment,
cure, or prevention of any disease. Statements regarding NAD+ reflect cellular biology and clinical experience and
are not medical claims. Eligibility for NAD+ therapy is determined by a licensed clinician based on individual
medical history. Do not use NAD+ if you have a known allergy or hypersensitivity to any component of the
preparation.
Warnings and Precautions
- Contraindications. Do not use NAD+ if you are pregnant, breastfeeding, attempting pregnancy, have active malignancy, or have a known allergy to any component of the compounded preparation. Pediatric use is not appropriate.
- Infusion and injection-related reactions. Flushing, warmth, chest pressure, transient nausea, lightheadedness, or muscle tension may occur, particularly when administration is rapid. Slowing the infusion rate or pausing administration typically relieves these sensations. Notify your provider immediately if symptoms persist or if you experience difficulty breathing, chest pain, palpitations, or severe headache.
- Injection site reactions. For subcutaneous preparations, transient redness, tenderness, or bruising at the injection site may occur.
- Hepatic or renal impairment. Inform your clinician of any liver or kidney disease, as dose adjustment or alternative therapy may be indicated.
- Not a substitute for evaluation or treatment. NAD+ is not a substitute for the evaluation, diagnosis, or treatment of any underlying medical condition. Seek appropriate medical care for persistent or unexplained symptoms.
Common Side Effects
Reported side effects are generally mild and transient. These may include:
- Flushing, sensation of warmth, or brief chest tightness (more common with rapid infusion)
- Transient nausea or abdominal discomfort
- Headache
- Fatigue, particularly during initial doses
- Injection site discomfort, redness, or bruising
- Lightheadedness
Drug Interactions
Clinical interaction data for parenteral NAD+ is limited. Disclose all prescription medications, over-the-counter products,
and dietary supplements to your clinician before starting NAD+ therapy. Particular caution is warranted for patients on
medications affecting hepatic metabolism, on chemotherapy regimens, or on therapies affecting sirtuin, PARP, or CD38
activity.
Compounded Product Notice
- NAD+ dispensed through the platform is compounded by a state-licensed 503A pharmacy pursuant to a patientspecific prescription.
- Compounded preparations are not evaluated or approved by the FDA for safety, efficacy, or quality.
- Active ingredients are obtained from FDA-registered facilities.
- Inactive ingredients (excipients) vary by formulation. Review the label and medication guide provided with your prescription and do not use the product if you have a known allergy to any component.
- If you observe any change in the appearance, color, clarity, or consistency of your medication, do not use it and contact your prescribing clinician or pharmacy immediately.
To report a suspected adverse reaction, contact the FDA MedWatch program at 1-800-FDA-1088 or
www.fda.gov/medwatch (http://www.fda.gov/medwatch), and notify your prescribing clinician. In a medical emergency,
call 911 or proceed immediately to the nearest emergency department.
4. Individual Results Disclaimer
Any testimonials, case histories, before-and-after images, or statistical references published by CaliberRx reflect the
experiences of specific individuals and are not representative of the results any particular patient may experience.
Clinical outcomes vary based on individual physiology, medical history, adherence to the prescribed regimen, concurrent
lifestyle factors, and the clinical judgment of the treating provider. CaliberRx does not guarantee any specific medical,
aesthetic, metabolic, or performance outcome. No statement on our website or in our marketing should be interpreted as
a promise of results.
5. Trademark Attribution and Affiliation Disclosure
CaliberRx LLC is not affiliated with, endorsed by, sponsored by, or otherwise connected to Novo Nordisk A/S, the owner
of the registered trademarks Ozempic®, Wegovy®, Rybelsus®, Saxenda®, and Victoza®. CaliberRx LLC is not affiliated
with, endorsed by, sponsored by, or otherwise connected to Eli Lilly and Company, the owner of the registered
trademarks Mounjaro®, Zepbound®, and Trulicity®. All third-party trademarks referenced in CaliberRx materials are the
property of their respective owners and are used only for identification and informational purposes.
Certain medications prescribed through the telehealth platform may be FDA-approved for indications other than the
purpose for which they are prescribed. Off-label prescribing is lawful when performed by a licensed clinician exercising
independent medical judgment.
6. Pricing, Membership, and Offer Terms
Prices displayed on our website and in marketing materials are subject to change and apply only to the CaliberRx
membership and administrative coordination services. Membership fees do not include the cost of medications, which are
billed separately by the dispensing pharmacy, nor the cost of clinical consultations, which are billed by the provider group.
Prescription eligibility and medication selection are determined solely by the evaluating clinician; no fee paid to CaliberRx
guarantees that you will receive a particular medication or any medication.
CaliberRx memberships are billed on a recurring subscription basis. Specific billing terms, trial offers, promotional
discounts, cancellation rights, and refund eligibility are set forth in our Terms of Service, Payment & Billing Consent,
Refund Policy, and Offer Terms, each available at caliberrx.co and incorporated by reference into these disclaimers.
7. Telehealth and Prescription Disclosures
CaliberRx-coordinated care is delivered via telehealth. A telehealth encounter differs from an in-person examination; in
limited situations, the absence of an in-person evaluation may affect the clinician’s ability to diagnose or treat certain
conditions. The evaluating clinician may determine that in-person care is required and may decline to prescribe.
Telehealth services are available only in states in which the provider group is licensed. A complete description of
telehealth rights, responsibilities, and limitations is included in our Telehealth Consent document, which patients
acknowledge before beginning care.
Prescriptions are issued pursuant to a valid patient-clinician relationship established through the platform. All
prescriptions are for personal, patient-specific use and may not be shared, resold, or transferred.
8. Emergency Information
CaliberRx and the clinicians coordinated through the platform do not provide emergency medical
services. If you are experiencing a medical emergency — including but not limited to chest pain, difficulty
breathing, signs of stroke, severe allergic reaction, suicidal thoughts, or any condition you believe is lifethreatening
— call 911 or go to the nearest emergency department immediately. If you are in a mental health
crisis, you may also reach the 988 Suicide and Crisis Lifeline by calling or texting 988.
9. Adverse Event Reporting
Suspected adverse reactions to any medication should be reported to the FDA’s MedWatch program by telephone at 1-
800-FDA-1088 or online at www.fda.gov/medwatch (http://www.fda.gov/medwatch). You are encouraged to also notify
your prescribing clinician and the dispensing pharmacy. Reporting safety concerns helps the FDA monitor the safety of
marketed products.
10. Contact Information
Contact Type
Details
General Inquiries
hello@caliberrx.co
Privacy Requests
privacy@caliberrx.co
Website
caliberrx.co
These disclaimers are incorporated into and supplemented by the CaliberRx LLC Terms of Service, Privacy Policy, Notice
of Privacy Practices, Telehealth Consent, Payment & Billing Consent, Refund Policy, State Privacy Law Addendum, SMS
Terms of Service, and Offer Terms, each available at caliberrx.co. CaliberRx reserves the right to modify these
disclaimers at any time with notice as required by applicable law. The version in effect at the time of your interaction with
our services governs.